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Prostaglandins (PG) are key mediators of diverse functions in the skin and several reports suggest that PG mediate
post-inﬂammatory pigmentary changes through modulation of melanocyte dendricity and melanin synthesis. The
proteinase-activated receptor 2 (PAR-2) is important for skin pigmentation because activation of keratinocyte PAR-
2 stimulates uptake of melanosomes through phagocytosis in a Rho-dependent manner. In this report, we show
that activation of keratinocyte PAR-2 stimulates release of PGE2 and PGF2a and that PGE2 and PGF2a act as
paracrine factors that stimulate melanocyte dendricity. We characterized the expression of the EP and FP receptors
in human melanocytes and show that human melanocytes express EP1 and EP3, and the FP receptor, but not EP2
and EP4. Treatment of melanocytes with EP1 and EP3 receptor agonists resulted in increased melanocyte
dendricity, indicating that both EP1 and EP3 receptor signaling contribute to PGE2-mediated melanocyte
dendricity. Certain EP3 receptor subtypes have been shown to increase adenosine 30,50-cyclic monophosphate
(cAMP) through coupling to Gs, whereas EP1 is known to couple to Gq to activate phospholipase C with elevation
in Ca2þ . The cAMP/protein kinase A system is known to modulate melanocyte dendrite formation through
modulation of Rac and Rho activity. Neither PGF2a or PGE2 elevated cAMP in human melanocytes showing that
dendricity observed in response to PGE2 and PGF2a is cAMP-independent. Our data suggest that PAR-2 mediates
cutaneous pigmentation both through increased uptake of melanosomes by keratinocytes, as well as by release of
PGE2 and PGF2a that stimulate melanocyte dendricity through EP1, EP3, and FP receptors.
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Melanocytes are neural crest-derived cells that reside in the
basal layer of the epidermis and provide photoprotection
to keratinocytes through the production and transfer of
melanin-laden organelles (melanosomes) to keratinocytes.
It has long been recognized that keratinocyte-derived
growth factors regulate melanocyte function in a paracrine
manner (Gordon et al, 1989). For example, keratinocytes
synthesize and secrete endothelin-1 in response to ultra-
violet irradiation (UVR) (Yohn et al, 1993; Tsuboi et al, 1995)
and keratinocyte-derived endothelin-1 increases melano-
cyte tyrosinase levels (Imokawa et al, 1997), dendricity
(Hara et al, 1995), and proliferation (Imokawa et al, 1992). a-
melanocyte-stimulating hormone (a-MSH) and its precursor
ACTH are produced by keratinocytes (Wakamatsu et al,
1997) and production is increased by UVR as well as the
inflammatory mediator interleukin-1 (Scholzen et al, 2000).
aMSH has well-known effects on melanocyte function
including proliferation, melanin production, and dendricity
(Abdel-Malek et al, 1995; Swope et al, 1995; Hunt et al,
1996; Suzuki et al, 1996). Therefore, UVR-induced stimula-
tion of keratinocyte-derived paracrine factors are important
regulators of cutaneous pigmentation through their effects
on melanocyte function.
The family of proteinase-activated receptors (PAR-1–4)
are G-coupled transmembrane receptors that are activated
by serine proteinases which cleave the extracellular amino
terminal domain of the PAR and expose a tethered ligand
that undergoes a conformational change with subsequent
activation of the receptor (for review see Macfarlane et al,
2001). In HaCat, PAR-2 is activated by trypsin, mast cell
tryptase, factor VIIa, or factor Xa and by synthetic peptides
that mimic the amino terminal portion of the receptor
(Santulli et al, 1995; Schechter et al, 1998; Steinhoff et al,
1999; Camerer et al, 2000; Scott et al, 2001). PAR-2 is
involved in a broad spectrum of physiological processes,
including induction of cytokine expression, mitogenesis,
and inflammatory responses (Mirza et al, 1997; Chi et al,
2001; Asokananthan et al, 2002). In human keratinocytes,
activation of PAR-2, either with trypsin or synthetic peptides
that mimic the tethered ligand, stimulates inositol phospho-
Abbreviations: PAR-2, proteinase-activated receptor-2; PG, pros-
taglandin; PKA, protein kinase A; SEM, standard error of the mean
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lipid hydrolysis and calcium mobilization (Santulli et al,
1995). PAR-2 activation also stimulates mitogen-activated
protein kinase in some cell types, resulting in proliferation,
whereas in keratinocytes PAR-2 activation inhibits growth
and differentiation (Derian et al, 1997). A central role for
PAR-2 in keratinocyte uptake of melanosomes has been
established (Sharlow et al, 2000; Seiberg et al, 2000a, b;
Seiberg, 2001) and we have shown that PAR-2 expression is
regulated by UVR in vivo and that PAR-2 expression differs
between individuals with different ability to tan (Scott et al,
2001). We recently showed that Rho, a small GTP-binding
protein involved in diverse cellular functions, including
stress fiber formation, is a critical and necessary signaling
intermediate involved in PAR-2-dependent phagocytosis
(Scott et al, 2003).
Prostaglandins (PG) are lipid molecules produced by
multiple cell types and have diverse effects at the cellular
and tissue levels including inflammation, wound repair,
angiogenesis, and cell proliferation. It is well known that
UVR stimulates the release of PG in the skin, primarily PGE2
and PGF2a (Hanson and DeLeo, 1990; Pentland and
Mahoney, 1990; Pentland et al, 1990) and abundant
amounts of PGE2 have been shown to be released from
keratinocytes following wounding (Pentland et al, 1987).
Recent reports show that activation of PAR-2 results in
release of PG in several cell types including urothelial cells
(Kubota et al, 2003), lung epithelial cells (Asokananthan
et al, 2002), guinea-pig gallbladder cells (Tognetto et al,
2000), and human fibroblasts (Frungieri et al, 2002). In
enterocytes, PAR-2 activation results in the release of
arachidonic acid and secretion of PGE2 and PGF2a (Kong
et al, 1997). Whereas multiple factors, including UVR,
cytokines, and wounding are known to stimulate PG release
from keratinocytes, a link between PAR-2 activation and PG
release in human keratinocytes is yet to be established.
Several reports suggest that PG function as paracrine
factors for melanocytes because PG modulate melanocyte
dendricity, proliferation, and tyrosinase expression. Abun-
dant literature on the effects of latanoprost (a PGF2a
analogue) on ocular tissue show that latanoprost results in
iris and eye lash pigmentation in patients treated with this
agent for glaucoma (Lindquist et al, 1999). The mechanisms
of latanoprost-induced pigmentation are yet to be deter-
mined (Grierson et al, 2001; Loeffler et al, 2001) although
increase in tyrosinase levels has been proposed to be
a factor (Hu, 2000; Hu et al, 2000; Prota et al, 2000;
Stjernschantz et al, 2000). Much less is known about the
effect of PG on human epidermal melanocytes; however,
several reports suggest that, similar to irideal melanocytes,
PG and arachidonic acid metabolites affect melanocyte
dendricity, melanization, and proliferation (Sauk et al, 1975;
Tomita et al, 1987; Morelli et al, 1989; Tomita et al, 1992;
Kashiwagi et al, 2002; Parsad et al, 2002). An early report
(Sauk et al, 1975) showed that in explanted anagen hair
bulbs PGE1, E2, and arachidonate stimulated cytoskeletal
rearrangement of filaments in melanocyte dendrites. In
another report, arachidonic metabolites PGD2, leukotriene
(LT) B4, LTC4, LTD4, LTE4, thromboxane (TX) B4, and
12-hydroxy eicosatetraenoic acid (12-HETE) resulted in
increased dendricity and tyrosinase in human epidermal
melanocytes whereas PGE1, PGF2a, and 6-ketoPGF1a had
no stimulatory effects (Tomita et al, 1992). In another report,
LTC4 and LTD4, were shown to enhance the growth of
human melanocytes (Morelli et al, 1989). Tomita et al (1987)
showed that PGE2 induced melanocyte dendricity.
PGE2 and PGF2a mediate their effects through G-protein
coupled receptors. The expression and second messenger
intermediates of PG receptors have not been defined in
human melanocytes. PGE2 has four receptors, EP1, EP2,
EP3, and EP4 (Coleman et al, 1995), and PGF2a has one
receptor, the FP receptor (Abramovitz et al, 1994; Pierce
et al, 1999). Of the four EP receptors, EP1 and EP2 are low-
affinity receptors for PGE2 (Kd 24 and 13 nM, respectively)
whereas EP3 and EP4 are high-affinity receptors (Kd 0.33
and 0.59 nM, respectively). The second messengers
activated by individual receptors differ, but in general, the
EP2 and EP4 receptors couple to Gs to stimulate adenosine
30,50-cyclic monophosphate (cAMP), and EP1 activates
phospholipase C (PLC) and phosphatidylinositol turnover
and stimulates the release of intracellular Ca2þ through
coupling to Gq. The FP receptor is a G-protein coupled
receptor which increases intracellular Ca2þ , indicating
signaling via PLC-mediated phosphoinositide turnover
(Lake et al, 1994). Whereas the EP3 receptor couples
predominantly to Gi, to inhibit cAMP (An et al, 1994), some
murine isoforms of EP3 have been shown to elevate cAMP
levels, either through coupling to Gs or indirectly through
augmentation of other G-protein coupled receptor’s cou-
pling to Gs (Negishi et al, 1996). EP3 is also known to
couple to PLC (Asboth et al, 1996).
In this report, we have studied the effect of PAR-2
stimulation on PG secretion in human keratinocytes and the
effect of PG on melanocyte dendricity as well as PGE2 and
PGF2a receptor expression in melanocytes. We show that
PAR-2 activation with short peptides that mimic the
tethered ligand of the receptor stimulates PGE2 and PGF2a
production in keratinocytes. When PGE2 or PGF2a were
added to melanocyte cultures, a significant increase in the
number and length of dendrites was observed. We show
that human melanocytes express EP1 and EP3, as well as
the FP receptor. Through the use of EP1 and EP3 receptor
agonists, we show that both EP1 and EP3 mediate PGE2-
dependent melanocyte dendricity. Because melanocyte
dendrite formation has been linked to cAMP-dependent
activation of Rac and inhibition of Rho (Busca et al, 1998;
Scott, 2002; Scott and Leopardi, 2003), we examined cAMP
levels in melanocytes treated with PGE2 or PGF2a. We show
that neither PGE2 nor PGF2a stimulates cAMP in melano-
cytes, showing that these PG stimulate dendrite formation in
a cAMP-independent manner. These data define PG receptor
expression in human melanocytes, and suggest that PAR-2
mediates cutaneous pigmentation both through regulation
of melanosome uptake, and through production of PG that
act as paracrine factors to stimulate melanocyte dendricity.
Results
Stimulation of PAR-2 results in PG release in keratino-
cytes To determine if activation of PAR-2 signals down-
stream to stimulate the production and release of PG,
HaCat, and human neonatal keratinocytes were treated with
the PAR-2-stimulating peptide SLIGRL-NH2 or its inactive
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control ISLLRG-NH2 at 400 mM. HaCat were treated in
DMEM without added calf serum; keratinocytes were
treated in KGM. Culture supernatants from HaCat were
collected and analyzed for PGE2 or PGF2a after 90 min, 6,
18, and 24 h. For experiments with neonatal keratinocytes,
culture supernatants were collected at 6, 18, and 24 h. Total
cellular protein was quantitated and levels of PG were
normalized against protein. Figures 1 and 2 show the
average fold change in PGE2 and PGF2a in SLIGRL-NH2
treated cells compared with ISLLRG-NH2 treated cells from
four separate experiments in HaCat and keratinocytes,
respectively. In HaCat, the PAR-2 activating peptide
resulted in a 2.2-fold increase in PGE2 over control cells
at 90 min (Fig 1A). After 6 h of treatment, PGE2 was
increased 3.1-fold and by 18 h PGE2 was increased 4.0-fold
over control cells. After 24 h of treatment with SLIGRL-NH2,
a 7.3-fold increase in PGE2 was seen in HaCat compared
with control cells. PGF2a in HaCat treated with SLIGLR-NH2
showed a 3.0-fold increase over ISLLRG-treated cells at
90 min (Fig 1B). After 6 and 18 h of treatment, PGF2a levels
were increased 3.3- and 3.5-fold, respectively, over control
cells. This was the maximal stimulation of PGF2a because
after 24 h of treatment with SLIGRL-NH2, PGF2a levels were
similar to the levels seen after 18 h of treatment. In neonatal
keratinocytes, PAR-2 activating peptides resulted in a 2.0-
fold increase in PGE2 over cells treated with inactive
peptides at 6 h, and a 1.8-fold increase at 18 h (Fig 2A).
After 24 h, treatment of keratinocytes with SLIGLR-NH2
resulted in a 2.5-fold increase in PGE2 compared with cells
treated with inactive peptides. PGF2a production increased
1.6-, 1.8-, and 1.7-fold after 6, 18, and 24 h of stimulation by
PAR-2 activating peptides, respectively (Fig 2B), in neonatal
keratinocytes.
To verify these results, we took advantage of NCTC 2544
cells, a keratinocyte cell line that lacks endogenous PAR-2
expression. NCTC 2544 cells arise from normal skin and
exhibit markers of epithelial differentiation by electron
microscopy (Ree et al, 1981) and lack endogenous PAR-2
Figure 1
Stimulation of proteinase-activated re-
ceptor 2 (PAR-2) results in the release
of prostaglandin (PG)E2 and PGF2a in
HaCat. (A and B) HaCat were treated with
the PAR-2-activating peptide SLIGRL-
NH2 or the inactive control peptide
ISLLRG-NH2 for the indicated time points
at a dose of 400 mM and PGE2 (A) and
PGF2a (B) were measured in culture
supernatants and normalized for total
cellular protein. Shown is the averaged
fold change in PGE2 and PGF2a in
SLIGRL-NH2-treated cells compared with
ISLLRG-NH2 treated cells from three
separate experiments. Triplicate samples
were run for each experiment: the data
presented represent the average of four
separate experiments  SEM.
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expression as demonstrated by RT-PCR (Kanke et al, 2001).
NCTC 2544 cells stably expressing human wild-type PAR-2
(Clone G) or vector expressing cells were treated with
SLIGRL-NH2 (400 mM) and PGE2 and PGF2a were assessed
in culture supernatants (Fig 3). Levels of PGE2 and PGF2a in
vector expressing cells and Clone G cells treated with the
non-specific peptide ISLLRG-NH2 were also assessed and
were low (approximately 30 pg per mg protein; data not
shown). Treatment of Clone G cells with SLIGRL-NH2 result-
ed in a marked increase in PGE2 production compared with
vector expressing cells (Fig 3A). A progressive increase in
PGE2 levels was observed over time in Clone G cells treated
with SLIGLR-NH2 from 171.9 pg per mg protein at 90 min to
555.1 pg per mg protein at 24 h. This represents a 4-fold
increase in PGE2 at 90 min compared with vector expres-
sing cells treated with SLIGLR-NH2 and a 21-fold increase
in PGE2 in Clone G cells compared with vector expressing
cells after 24 h of treatment. PGF2a levels in Clone G cells
treated with SLIGLR-NH2 also increased compared with
vector expressing cells (Fig 3B). After 90 min and 6 h, PGF2a
was 55 and 65 pg per mg protein, respectively (22- and
50-fold increase over vector-expressing cells, respectively)
and after 18 and 24 h PGF2a was 181 and 271 pg per mg
protein, respectively (39- and 52-fold increase over vector-
expressing cells, respectively).
PGE2 and PGF2a induce dendricity in human melanocy-
tes Dendrites are a characteristic morphologic feature of
melanocytes and are necessary for melanosome transfer to
keratinocytes and effective photoprotection. We assessed
the effect of PGE2 and PGF2a on melanocyte dendricity
(number of dendrites per cell) and dendrite length after 6 d
of treatment (Fig 4). Because growth factors in melanocyte
media stimulate dendrite formation, analysis of the effects
of PGE2 and PGF2a on dendrite length and number were
performed in media lacking basic fibroblast growth factor
and bovine pituitary extract in which cells are predominantly
bi-polar (personal observation). Preliminary experiments in
which bovine calf serum was also omitted from the media
were performed but cells failed to survive in this depleted
media. Phorbol esters were included in the media to support
viability. Previous studies have shown that endogenously
Figure 2
Stimulation of proteinase-activated receptor 2 (PAR-2) results in
the release of prostaglandin (PG)E2 and PGF2a in neonatal
keratinocytes. (A and B) Human neonatal keratinocytes were treated
with the PAR-2-activating peptide SLIGRL-NH2 or the inactive control
peptide ISLLRG-NH2 for the indicated time points at a dose of 400 mM
and PGE2 (A) and PGF2a (B) were measured in culture supernatants and
normalized for total cellular protein. Shown is the averaged fold change
in PGE2 and PGF2a in SLIGRL-NH2-treated cells compared with
ISLLRG-NH2-treated cells from four different Caucasian foreskins.
Triplicate samples were run for each experiment: the data presented
represent the average of four separate experiments  SEM.
Figure3
NCTC 2544 cells stably expressing proteinase-activated receptor 2
(PAR-2), but not vector expressing cells, produce prostaglandin
(PG)E2 and PGF2a in response to PAR-2 activation. (A and B) NCTC
2544 cells stably expressing wild-type PAR-2 (Clone G) or cells
expressing vector alone were treated with SLIGLR-NH2 (400 mM) for
various time points and PGE2 (A) and PGF2a (B) were measured in
culture supernatants and normalized for total cellular protein. Triplicate
samples were run for each experiment: the data presented represents
the average of three separate experiments  SEM.
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produced PG may downregulate EP receptors (Hashimoto
et al, 1991; Li et al, 1993) which could diminish the effect of
exogenous PG on dendricity. We therefore first assessed the
endogenous production of PGE2 and PGF2a in human mela-
nocytes grown in growth factor depleted medium. Culture
supernatant from 2  105 cells from two separate cultures
of Caucasian melanocytes grown in depleted medium for
24 h were assessed for PGE2 and PGF2a. The average amount
of PGE2 and PGF2a was very low in culture supernatant of
melanocytes grown in growth factor depleted media (27.5
and 25.5 pg per mL, respectively, data not shown). Therefore,
it is unlikely that this low level of endogenous PG resulted in
modulation of receptor expression.
We observed a statistically significant (po0.05) increase
in the percentage of melanocytes with more than two
dendrites in cells treated with PGE2 and PGF2a at both
doses tested (30 and 300 nM) compared with untreated
cells (Fig 4A). PGF2a was more effective in stimulating
dendrite formation compared with PGE2 because even the
lower dose of PGF2a (30 nM) resulted in greater dendricity
than the higher dose of PGE2 (300 nM). Changes in dendrite
length (Fig 4B) also were noted in treated cells, although
only cells treated with PGF2a showed statistically significant
increases in dendrite length compared with untreated cells.
Shown in Fig 4C are representative photographs of
melanocytes treated with PGE2 or PGF2a (300 nM). Control
cells show a typical bipolar morphology with few arborizing
dendrites. In contrast, cells treated with either PGE2 or
PGF2a show cells with multiple complex dendrites.
PGE2 and PGF2a do not stimulate cAMP in human
melanocytes PGE2 mediates its effects through binding to
the family of EP receptors. Of the four EP receptors EP2,
EP3, and EP4 couple to adenylate cyclase. In the case of
EP2 and EP4, this results in elevated cAMP through
coupling to Gs. In the case of EP3, depending on the splice
variant expressed in the cell, coupling to both Gi and Gs has
been demonstrated, resulting in both inhibition and stimula-
tion of adenylate cyclase (Adam et al, 1994; Aoki et al,
1999); however, the primary action of EP3 is to inhibit cAMP.
Growth factors that stimulate the cAMP second messenger
pathway, such as aMSH stimulate dendrite formation
(Hirobe, 1992) and activation of adenylate cyclase by
forskolin has also been shown to stimulate melanocyte
dendricity. Work by our group and others has shown that
cAMP-dependent dendricity in melanocytes occurs through
inhibition of Rho and activation of Rac (Busca et al, 1998;
Scott, 2002; Scott and Leopardi, 2003). We therefore
examined the effect of PGE2 and PGF2a on cAMP in
melanocytes from four separate cell lines (Fig 5). Human
melanocytes were pre-treated with indomethacin to block
endogenous PG production and were then treated with
PGE2 (Fig 5A) or PGF2a (Fig 5B) for 60 min in the presence of
IBMX. Treatment of melanocytes with PGE2 at a dose of
280 nM (Fig 5A) resulted in a small but statistically
insignificant (po0.16) increase in cAMP levels. Similarly,
treatment of melanocytes with PGF2a did not result in a
statistically significant increase in cAMP levels (Fig 5B).
Human melanocytes express EP1, EP3, and FP recep-
tors We next characterized the EP receptors expressed by
melanocytes, and confirmed expression of the FP receptor.
Western blotting for EP1, EP2, EP3, and EP4 was per-
formed on human melanocyte total cellular protein (Fig 6).
Human keratinocytes, which are known to express EP1,
EP2, and EP4, were used as positive controls for EP1, EP2,
and EP4 blots; rat brain was used as a positive control for
EP3 blots. Of the EP receptors, human melanocytes
express only EP1 and EP3. Even when large amounts of
protein (75 mg) were loaded onto the gel, and even after
prolonged exposure of the film (overnight) we failed to
detect either EP2 or EP4 in melanocyte lysates. Steady-
state levels of EP1 were greater in keratinocytes than
melanocytes. EP3 receptor expression was much greater in
melanocytes than keratinocytes; however, a faint but
detectable band was observed in keratinocyte lysates in
blots with longer exposures (data not shown). Higher levels
of steady-state expression of the FP receptor were
observed in melanocytes compared with keratinocytes.
We next analyzed melanocyte and keratinocyte RNA for
expression of EP and FP receptor message (Fig 6B). No
detectable message for EP2 or EP4 was observed in
melanocyte RNA, whereas keratinocytes expressed EP2
and EP4 mRNA (data not shown). Bands of the expected
size were present for EP3 (597 kb) and FP receptors (237
kb) in melanocytes (Fig 6B). We were unable to amplify the
EP1 receptor from either keratinocytes or melanocyte RNA,
despite using three different sets of primers (data not
shown), and despite detection of EP1 protein on Western
blots. This may be because of the high GC content of the
EP1 receptor coding region (approximately 70%–80%
throughout). We are confident that the band detected for
EP1 on Western blots is specific, because the antibody
used has been demonstrated to detect EPI, but not other
EP receptor subtypes (Konger et al, 2002).
EP1 and EP3 agonists both induce dendricity in human
melanocytes We utilized EP receptor agonists to determine
if EP1, EP3 or both are involved in melanocyte dendricity.
Each subtype of PGE2 receptor exhibits a unique profile of
activation by these agonists (Coleman et al, 1995) which
are PG derivatives that bind specific EP receptor sub-
types with higher affinity than other subtypes (Savage
et al, 1993; Coleman et al, 1995; Katsuyama et al, 1995).
Human melanocytes from four separate cultures were
treated with either misoprostol (EP3/EP2 agonist) or
17-phenyl trinor (EP1 agonist) for 6 d in growth factor-
depleted medium and dendricity was assessed (Fig 7).
Neither of the agonists induced a statistically significant
increase in dendrite length, consistent with results obtained
from PGE2-treated cells (data not shown). In contrast, the
number of dendritic projections was markedly increased
in melanocytes treated with both agonists, with a relative
potency of misoprostol greater than 17-phenyl trinor. In
control cells, only 2% of cells exhibited more than two
dendrites. In cells treated with misoprostol at 500 nM, 40%
of cells had more than two dendrites and at 10 mM
misoprostol, 54% of cells had more than two dendrites.
The EP1 agonist 17-phenyl trinor also induced a dendritic
phenotype, with 36% of cells exhibiting more than two
dendrites following treatment with 10 mM 17-phenyl trinor.
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Misoprostol is known to activate both EP4 and EP3
receptors (Fedyk and Phipps, 1996); however, because
melanocytes do not express detectable amounts of the EP4
receptor, we conclude that effects of misoprostol on
melanocyte dendricity are through the EP3 receptor. From
these data, we conclude that both EP1 and EP3 receptors
mediate PGE2-induced melanocyte dendricity.
Discussion
PG, the products of arachidonic acid cyclooxygenation,
regulate a broad range of physiological processes, such as
inflammation, immune responses, and cell growth and
differentiation. In this report, we have linked production of
PGE2 and PGF2a to PAR-2 activation in keratinocytes. Our
Figure 4
Prostaglandin (PG)E2 and PGF2a increase dendricity in human melano-
cytes. (A and B) Human melanocytes from two separate foreskins
were cultured in depleted medium in the presence or absence of PGE2 or
PGF2a for 6 d. Doses tested were 30 and 300 nM. The percentage of cells
with more than two dendrites (A) and dendrite length (B) was calculated as
described in Materials and Methods. Results represent the average of two
experiments  SEM in which at least 30 cells were analyzed for each set.
Asterisks indicate statistically significant different from untreated cells
(po0.05). (C) Representative photographs of human melanocytes treated
with PGE2 (300 nM) or PGF2a (300 nM) for 6 d. Untreated control cells are
predominantly bi-polar. In contrast, cells treated with either PGE2 or PGF2a
show numerous elongated and arborizing dendrites. Bar¼50 mm.
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data show that activation of PAR-2 with peptides that mimic
the tethered ligand of the receptor stimulates the rapid re-
lease of PGE2 and PGF2a. These data were confirmed using
a keratinocyte cell line expressing wild-type PAR-2, in which
a marked increase in PGE2 and PGF2a was observed
following PAR-2 stimulation compared with vector expres-
sing cells that lack PAR-2. These data are consistent with
reports of PAR-2-mediated PG production in other cell
types (Kong et al, 1997; Tognetto et al, 2000; Asokananthan
et al, 2002; Robin et al, 2003). Although the mechanisms by
which PAR-2 mediates PG release in other cells is still being
explored, recent data suggest that PAR-2-dependent acti-
vation of Ca2þ -independent phospholipase A(2) mediates
PGE2 release (McHowat et al, 2001; Kubota et al, 2003).
PAR-2 signaling has been shown to mediate melanosome
uptake in the skin in vitro and in vivo through phagocytosis
that is Rho-dependent (Scott et al, 2003). We now show that
PAR-2 activation results in release of PG, and that PG
stimulate melanocyte dendricity. These results suggest that
PAR-2 activation modulates skin pigmentation in multiple
ways, both through direct action on keratinocyte uptake of
melanosomes and through release of PG that function as
paracrine factors that stimulate melanocyte dendricity, and
potentially other aspects of melanocyte function.
Results from previous investigations into the effects of
PG on melanocytes are conflicting, with some studies
showing an effect of PG on melanocyte dendricity (Sauk
et al, 1975; Tomita et al, 1987, 1992), whereas others
have shown little or no effects (Gordon et al, 1989). These
differences may reflect differences in dosages and culture
medium in individual experimental systems. In this report,
we show that the addition of very low doses of PGE2 and
PGF2a to human melanocyte cultures results in a significant
increase in melanocytes dendricity and dendrite length. We
performed preliminary experiments in which we tested the
effects of PGE2 and PGF2a in human melanocytes grown in
complete media, and although a statistically significant
effect on melanocyte dendricity was noted, the results were
not marked (data not shown). But when we analyzed the
effect of PG on melanocyte dendricity in media lacking
basic fibroblast growth factor and bovine pituitary extract, a
marked change in dendricity was observed compared with
untreated cells. This is most likely due to a lowering of
growth factor-induced dendrite-stimulating signaling path-
ways in cells grown in depleted media. It is beyond the
scope of this work to analyze the effects of PGE2 and PGF2a
on other aspects of melanocyte function, such as proli-
feration and pigmentation. But because melanocytes
expressed multiple receptors for PG which potentially
stimulate multiple signaling pathways (see below) it is likely
that PGE2 and PGF2a modulate other aspects of melano-
cyte function, and that the effects of PG on these aspects of
melanocyte biology are related to distinct PG–receptor
ligand interactions.
In order to determine the mechanisms by which PGE2
and PGF2a modulate melanocyte dendricity, a detailed
analysis of EP and FP receptor signaling intermediates will
be necessary. In this report, we show that melanocytes
express two of the four PGE2 receptors, EP1 and EP3, as
well as the FP receptor. We also show that there are
differences in the steady-state levels of EP and FP receptor
expression between melanocytes and keratinocytes, with
melanocytes expressing more EP3 and FP receptor than
keratinocytes, and keratinocytes expressing greater
amounts of EP1. Because certain EP3 isotypes have been
shown to couple to Gs and because the cAMP/PKA (protein
kinase A) pathway is known to stimulate melanocyte
dendrite formation through activation of Rac and inhibition
of Rho, we first asked whether treatment of melanocytes
with PGE2 or PGF2a results in increased cAMP. We show
that PGE2 and PGF2a do not increase cAMP in human
melanocytes; therefore, the mechanism by which PGE2 and
PGF2a mediate melanocyte dendrite formation is through a
cAMP-independent pathway. Although the cAMP/PKA
pathway is the best-characterized pathway known to be
involved in melanocyte dendrite formation, multiple signal-
ing pathways modulate Rac and Rho activity in diverse cell
types. Each one of EP1, EP3, and FP receptors has been
shown to signal through PLC and in human platelets, Rac
has been shown to be activated by a PLC-dependent
mechanism (Soulet et al, 2001). Therefore, it is possible that
PGE2 and PGF2a mediate melanocyte dendricity through
the PLC-protein kinase C pathway. Alternatively, melano-
cyte dendricity could be mediated through second mes-
senger systems that regulate cytoskeletal proteins. It is
known, for example, that endothelin-1, a potent stimulant
for melanocyte dendricity (Hara et al, 1995), activates
multiple second messenger pathways, including protein
kinase C (Imokawa et al, 1996), cAMP/PKA, and PLC
resulting in increased intracellular Ca2þ (Kang et al, 1998).
PLC cleaves phosphatidylinositol (4,5)-bisphosphate (PIP2)
into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol and
PIP2 serves as a binding site for various proteins that modify
actin (Chou et al, 2002). Therefore, EP1/EP3 and FP
receptors could potentially stimulate melanocyte dendricity
Figure 5
Treatment of human melanocytes with prostaglandin (PG)E2 and
PGF2a has no effect on cAMP. Human melanocytes were treated with
PGE2 (A) or PGF2a (B) for 60 min in the presence of indomethacin and
isobutyl methyl xanthine and cAMP was measured in cell lysates.
Shown is the averaged level of cAMP (pmol per mL) from melanocyte
cultures from four separate Caucasian foreskins  SEM. There were no
significant changes in levels of cAMP in response to either PGE2 or
PGF2a treatment.
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through PLC-dependent mechanisms. Future studies will be
directed at examining the signaling intermediates of the
EP1, EP3, and FP receptors and determination of Rac and
Rho activities in response to receptor activation.
In summary, we have demonstrated a novel role for the
PAR-2 receptor in the regulation of cutaneous pigmentation
through its ability to activate downstream signals that
stimulate PGE2 and PGF2a synthesis and release. We have
shown that PGE2 and PGF2a stimulate human melanocyte
dendricity, and have defined the expression of the PGE2
and PGF2a receptors at the protein and message levels in
melanocytes. Based on the expression of the PGE2
receptor subtypes EP1 and EP3, but not EP2 and EP4
on human melanocytes, PGE2-dependent dendricity is
Figure 6
Human melanocytes express EP1, EP3, and FP receptors. (A) Western blots of human melanocyte (HM) and human keratinocytes (HK) for the EP
and FP receptors. Shown are 12% SDS-PAGE. Melanocytes express EP1, EP3, and FP receptors, but not EP2 and EP4. Steady-state levels of EP
and FP expression differ between melanocytes and keratinocytes, with keratinocytes expressing more EP1 than melanocytes, and melanocytes
expressing more EP3 and FP receptor compared with keratinocytes. Results are representative blots from cells of at least two individual foreskins.
(B) RT-PCR of melanocytes and keratinocyte RNA for EP3 and FP receptors. PCR products of the expected size were amplified for the EP3 (597 Kb)
and FP receptors (237 Kb) from human melanocyte RNA and visualized on 1% agarose gels stained with ethidium bromide. Keratinocytes
expressed a detectable FP receptor PCR product and a faint EP3 receptor product. Negative control (NC) consisted of a PCR reaction without
template. RT-PCR of b-actin served as a positive control.
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mediated through one or perhaps both of these receptors.
Experiments in which agonists of EP1 and EP3 receptors
both induced melanocyte dendricity support this conclu-
sion. These data point to a novel mechanism by which
PAR-2 mediates cutaneous pigmentation through receptor-
stimulated PG production, and characterize PG receptor
expression in normal human melanocytes.
Materials and Methods
Reagents Vitrogen 100 was purchased from Cohesion (Palo Alto,
California); Dulbeccos minimal essential media (DMEM) and fetal
bovine serum was purchased from CellGro (Herndon, Virginia). The
BCA Protein Assay kit was purchased from Pierce Chemical,
(Rockford, Illinois). The specific PAR-2 activating peptide (SLIGRL-
NH2) and its inactive control (ISLLRG-NH2) were synthesized by
Research Genetics (Huntsville, Alabama). Peptide purity was
greater than 95% as determined by high-performance liquid
chromatography. ELISA kits for analysis of PGE2 and PGF2a were
purchased from Cayman Chemicals (Ann Arbor, Michigan). EP
receptor agonists (misoprostol and 17-phenyl trinor PGE2) were
purchased from Cayman Chemicals. Monoclonal antibodies to the
human EP1 and EP2 receptors were a generous gift of Dr Ray-
mond Konger (Indiana University School of Medicine, Indianapolis,
Indiana) and have been described previously (Konger et al, 2002).
EP3 and EP4 polyclonal antibodies were purchased from Santa
Cruz Biotechnology (Santa Cruz, California); FP receptor polyclonal
antibodies were purchased from Cayman Chemical. Horseradish
peroxidase-conjugated goat anti-mouse and anti-rabbit antibo-
dies, indomethacin, and 2 mM isobutyl methyl xanthine (IBMX)
were purchased from Sigma Co (St Louis, Missouri).
Cells and cell culture Human HaCat (a gift from Dr N. E. Fusenig,
Heidelberg, Germany) were maintained in DMEMþ 10% fetal
bovine serum. The keratinocyte cell line NCTC2544 (Ree et al,
1981) expressing empty vector (pRc/RSV; Invitrogen, Carlsbad,
CA) or stably transfected NCTC cells expressing human wild-type
PAR-2 (Clone G) were a generous gift from Dr Robin Plevin
(University of Strathclyde, Glasgow, Scotland). NCTC2544 cells are
a keratinocyte cell line that lacks expression of the PAR-2 receptor
(Kanke et al, 2001). Prior studies have established that PAR-2
receptor expression, as assessed by mRNA expression, is similar
between Clone G cells and human keratinocytes (Kanke et al,
2001). Neonatal foreskins were obtained according to the
University of Rochester Research Subjects Review Board guide-
lines and were the source of human keratinocytes and melano-
cytes. Epidermal suspensions were cultured in keratinocyte-SFM
(Gibco-BRL, Carlsbad, California) as previously described (Scott
and Haake, 1991). Human melanocytes were cultured from
Caucasian foreskins in MCDB 153 (Sigma Co.) supplemented with
0.5% fetal bovine serum, bovine pituitary extract (15 mg per mL),
phorbol ester (8 nM), basic fibroblast growth factor (1 ng per mL),
insulin (5 mg per mL), and hydrocortisone (500 ng per mL). Supp-
lements were obtained from Sigma Co. All cells were maintained at
371C in 5% CO2 (vol/vol). For experiments analyzing the effects of
PG on melanocyte dendricity, cells were cultured in medium
lacking basic fibroblast growth factor and bovine pituitary extract
(‘‘growth factor-depleted medium’’). Melanocytes survive well in
this medium because of the presence of phorbol esters and cells in
this medium are predominantly bi-polar (personal observation).
Cyclic-AMP assays Primary human melanocytes (2.5  105 cells
per well) were cultured in 6-well plates. Two days after plating
indomethacin at a final concentration of 3 mg per mL was added to
the cultures for 18 h to block endogenous PG production. At the time
of the assay, media was replaced with serum and growth factor free
pre-warmed MCDB-153 for 1 h prior to the addition of PG. IBMX
was added to inhibit phosphodiesterase activity and indomethacin
was present in the media throughout the incubation. cAMP levels
were measured using the Direct Cyclic AMP EIA kit with acetylation
as per manufacturers instructions (Assay Design, Inc., Ann Arbor,
Michigan). The plate was read on a Finstrument microplate Reader
(MTX Lab Inc., Vienna, Virginia) and the data were analyzed with
Deltasoft 3 software (BioMetallics, Inc., Princeton, New Jersey)
using a weighted four-parameter logistic curve-fitting program.
Western blotting For analysis of FP and EP receptor expression
cells were lysed in RIPA buffer (150 mM NaCl, 1%NP-40, 0.5% DOC,
0.1% SDS, 50 mM Tris-HCl) with protease inhibitors (Boehringer
Mannheim, Gmbt, Germany). Protein was quantitated using bovine
serum albumin as standard (Bio-Rad Laboratories, Hercules,
California) and protein was resolved on 12% SDS-PAGE gels.
Visualization of the immunoreactive proteins was accomplished with
an enhanced chemiluminescence reaction (Pierce Chemical).
Melanocyte dendricity assay For analysis of dendricity, melano-
cytes were subcultured onto vitrogen coated cover slips (1  105
cells) in growth factor-depleted medium and were treated with PG
or EP receptor agonists for 6 consecutive days in fresh media.
PGE2 and PGF2a were used at two doses (30 and 300 nM).
Agonists were used at 0.5, 5, and 10 mM. Following treatment, cells
were fixed in 3.7% formalin/phosphate-buffered saline, stained
with hematoxylin and digital photographs from three 40  fields
were obtained using a Spot Digital camera (Diagnostics Instru-
ments, Sterling Heights, Michigan). The number of dendrites per
cell was determined for all cells in each 40  field. For analysis of
dendrite length, the length of the dendrite from the cell nucleus to
the dendrite tip was measured using Spot software for each cell in
the field. Approximately 120 cells were analyzed from two separate
cell lines derived from Caucasian foreskins.
RT-PCR Total RNA was isolated from human foreskin keratinocyte
and melanocyte cell cultures using Trizol reagent (Gibco BRL,
Gaithersberg, Maryland) according to manufacturers instructions.
Reverse transcription was performed using 75 mg of total RNA with
SuperScript II reverse transcriptase (Invitrogen, Carlsbad, Califor-
nia). PCR of the EP and FP receptors was performed using the
Qiagen HotStarTaq Master Mix. The primers used are as follows.
EP2 (fwd: CGGACCGCTTACCTGCAGCTG, rvs: TAATGAAATCC-
GACAACAGAG), EP3 (fwd: AGCAGCGTTGGGAGCACATCG, rvs:
GCAGTGCTCAACTGATGTCTG), EP4 (fwd: ATCGACTGGACCAC-
CAACGTGACG, rvs: TCTATTGCTTTACTGAGCACTGTC), FP (fwd:
Figure 7
Treatment of melanocytes with EP1 and EP3 receptor agonists
induces dendricity. Human melanocytes from four separate Cauca-
sian foreskins were treated for 6 d with the EP1 agonist 17-phenyl trinor
(17-PT) or the EP3/EP2 receptor agonist misoprostol (MP) in growth
factor-depleted medium. Cells were then fixed in formalin, stained with
hematoxylin and the percentage of cells with more than two dendrites
was determined from digital photographs of five 40  fields. Whereas
both 17-phenyl trinor and misoprostol induce dendricity, misoprostol
was more potent. Shown are the averaged results from the four
cultures  SEM.
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ATGCAAACAAACCGAAGC; rvs: ATTGCCAGTCTTCCCCTC). The
PCR conditions for amplification of EP3 and EP4: initial denaturation
951  150, denaturation 941  300, annealing 561  300, extension
721  300, final extension 721  100. The PCR conditions for
amplification of FP was: initial denaturation 951  15, denaturation
941  300, annealing 601  300, extension 721  400, final extension
721  70. Denaturation, annealing, and extension were performed for
40 cycles. PCR products were run on a 1% agarose gel containing
ethidium bromide. RT-PCR of b-actin served as a positive control.
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